Pt(II) Rollover Cyclometalated Complexes Supported by 2,2'-Bipyridine N‑Oxide: Synthesis, Characterization, and Biological Evaluation.

Authors

Antonio Zucca, Giacomo Senzacqua, Antonio Canu, Fabrizio Ortu, Sergio Stoccoro, Maria I Pilo, Germano Orrù, Giuseppina Pichiri, Sara Fais, Alessandra Scano

Published in

Organometallics. Volume 45. Issue 14. Pages 1698-1711. Jul 27, 2026. Epub Jul 14, 2026.

Abstract

Four platinum-(II) rollover cyclometalated complexes derived from 2,2'-bipyridine N-oxide (bpy^NO), [Pt-(bpy^NO-H)-(DMSO)-Me] (1a), [Pt-(bpy^NO-H)-(PPh₃)-Me] (2a), [Pt-(bpy^NO-H)-(DMSO)-Cl] (3a), and [Pt-(bpy^NO-H)-(PPh₃)-Cl] (4a), were synthesized, characterized, and evaluated for their antimicrobial and cytotoxic activities. The electron-poor nature of bpy^NO enables rollover C-H bond activation at room temperature. NMR and X-ray analysis (4a) revealed distinctive features, including an intramolecular interaction between the H^3' hydrogen and the N-oxide oxygen. A correlation between the direct ¹⁹⁵Pt-³¹P coupling constant and the donating properties of cyclometalated ligands has been found, allowing a useful scale of donor properties. A preliminary screening of antimicrobial activity against E. coli, K. pneumoniae, S. aureus multidrug resistant (MDR), S. pyogenes, P. aeruginosa, and C. albicans demonstrated selective activity. Complex 3a showed the most promising results against E. coli and multidrug-resistant S. aureus. Significantly, the complexes also exhibited biofilm inhibitory behavior; notably, complex 1a showed activity against K. pneumoniae. Additionally, preliminary cytotoxicity tests on human tumor (HT29) cells and normal (CCD 841 CoN) cells were performed. Among the investigated compounds, 1a, 2a, and 3a exhibited a significant reduction in tumor cell viability, whereas complex 4a displayed moderate activity. These results establish 2,2'-bipyridine N-oxide as a promising ligand scaffold for developing platinum complexes.

PMID:
42529740
Bibliographic data and abstract were imported from PubMed on 30 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.